Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMITID vs ANEXSIA 5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Irritable bowel syndrome,Enuresis
Management of moderate to moderately severe pain where an opioid analgesic is appropriate
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
Hepatic via CYP2D6, CYP2C19, CYP3A4; active metabolite nortriptyline.
Hydrocodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (hydromorphone). Acetaminophen: hepatic metabolism via conjugation (glucuronidation, sulfation) and CYP2E1-mediated oxidation to toxic NAPQI.
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
90-95% bound primarily to albumin and α1-acid glycoprotein.
Oxycodone: 38-45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10-25% bound to albumin at therapeutic concentrations.
3-5 L/kg; indicates extensive tissue distribution.
Oxycodone: Vd 2.0-3.0 L/kg; distributes extensively into tissues. Acetaminophen: Vd 0.8-1.0 L/kg; relatively uniform distribution.
Oral: 60-70%; Intravenous: 100%.
Oxycodone: oral bioavailability 60-87% (immediate-release). Acetaminophen: oral bioavailability 88-98% (therapeutic doses).
GFR ≥30 m L/min: no adjustment. GFR 15–29 m L/min: reduce dose by 50%. GFR <15 m L/min: contraindicated or use with extreme caution, maximum 25 mg/day.
GFR 30-50 m L/min: use with caution, increase dosing interval to every 6 hours; GFR <30 m L/min: avoid use due to hydrocodeone accumulation.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: contraindicated.
Not FDA-approved for use in children <12 years. For adolescent depression (off-label): start 25 mg/day, titrate up to 50–100 mg/day. Weight-based: 1–3 mg/kg/day, not to exceed 150 mg/day.
Not recommended for children under 18 years due to risk of respiratory depression.
Start at 10–25 mg orally at bedtime; increase by 10–25 mg every 3–7 days to effective dose, typically 50–75 mg/day. Maximum 100 mg/day due to increased risk of anticholinergic effects, sedation, and orthostatic hypotension.
Start with lowest dose (1 tablet every 6 hours), monitor renal and hepatic function, and avoid in frail elderly due to increased fall and cognitive impairment risk.
Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from acetaminophen overdose.
Clinical worsening and suicide risk,Serotonin syndrome,Cardiovascular effects (QT prolongation, arrhythmia),Anticholinergic effects,Seizures,Angle-closure glaucoma,Urinary retention,Hepatic impairment,Hyponatremia
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; seizure; and serotonin syndrome.
Hypersensitivity to amitriptyline,Concomitant use with MAOIs (within 14 days),Acute recovery phase after myocardial infarction,Concurrent use of cisapride or other QT-prolonging drugs
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; severe hepatic impairment; and concurrent use of MAOIs within 14 days.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Tyramine-rich foods (aged cheese, cured meats, fermented products) should be limited due to risk of hypertensive crisis. Maintain adequate fluid intake to prevent constipation.
Avoid alcohol. Grapefruit juice may enhance side effects; limit intake. Take with food to reduce gastrointestinal discomfort.
First trimester: Amitriptyline (likely the active ingredient in AMITID) is associated with a small increased risk of congenital malformations, particularly cardiovascular defects, based on observational studies. Absolute risk is low. Second and third trimesters: Chronic use may lead to neonatal adaptation syndrome (irritability, respiratory distress) and anticholinergic effects (e.g., constipation, urinary retention). Late third trimester exposure may increase risk of persistent pulmonary hypertension of the newborn (PPHN).
First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal renal toxicity, oligohydramnios, and premature closure of ductus arteriosus. Use only if clearly needed.
Amitriptyline and its active metabolite nortriptyline are excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5–1.5. Relative infant dose is low (estimated <2% of weight-adjusted maternal dose). No adverse effects reported in infants followed prospectively. The American Academy of Pediatrics considers amitriptyline compatible with breastfeeding. However, monitor infant for sedation, poor feeding, and growth.
Paracetamol and hydrocodone are excreted in breast milk. M/P ratio: paracetamol ~1.0, hydrocodone ~1.0-2.0. Use with caution; monitor infant for drowsiness and respiratory depression. Consider risk of infant sedation with long-term use.
Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism, renal clearance) may reduce serum drug concentrations. Therapeutic drug monitoring (if available) can guide dose adjustments; clinical response may require dose increases by 30–50% in the second and third trimesters. Avoid abrupt withdrawal; taper if discontinuing.
Increased clearance in pregnancy may require dose adjustment. Monitor for pain control and adverse effects; no fixed dose change recommended. Consider lower starting dose due to potential fetal risks. Avoid chronic use; taper if possible.
Amitriptyline is a tricyclic antidepressant with strong anticholinergic effects; monitor for QT prolongation, especially in elderly or those with cardiac disease. Start low (10-25 mg at bedtime) and titrate slowly. Avoid in recent MI, narrow-angle glaucoma, and urinary retention. Use with caution in seizure disorders.
ANEXSIA 5/325 contains hydrocodone 5 mg and acetaminophen 325 mg. Maximum acetaminophen dose from all sources should not exceed 4 g/day in adults; avoid in severe hepatic impairment. Hydrocodone is a Schedule II controlled substance with abuse potential; monitor for respiratory depression, especially in opioid-naive patients. Use with caution in patients with COPD, sleep apnea, or increased intracranial pressure. Consider naloxone co-prescription for high-risk patients. For acute pain, limit duration to 3-7 days.
Take this medication at bedtime as it may cause drowsiness.,Avoid alcohol and other CNS depressants.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,May cause dry mouth, constipation, blurred vision; report severe side effects like fainting or irregular heartbeat.,Full therapeutic effect may take 2-4 weeks.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or other sedatives (e.g., benzodiazepines) while taking this medication.,Avoid other products containing acetaminophen (e.g., Tylenol, cold remedies) to prevent liver damage.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of others; dispose of unused medication via drug take-back programs.,Seek emergency help if you have trouble breathing, severe drowsiness, or signs of allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMITID vs ANEXSIA 5/325, answered by our medical review team.
AMITID is a Tricyclic Antidepressant that works by Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.. ANEXSIA 5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMITID and ANEXSIA 5/325 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMITID is: 75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.. The standard adult dose of ANEXSIA 5/325 is: 1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMITID and ANEXSIA 5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMITID is classified as Category C. First trimester: Amitriptyline (likely the active ingredient in AMITID) is associated with a small increased risk of congenital malformations, particularly cardiovascular defects, . ANEXSIA 5/325 is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.